Founded in 2021, A28 Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the development of its targeted oncolytic peptide platform for the treatment of multiple cancer types. Our lead proprietary agent, AT-101, has demonstrated the potential to deliver safe and effective cancer treatment alone and in combination with multiple classes of cancer medications including immuno-oncology medications and chemotherapy. Our lead indications are metastatic ovarian cancer with liver metastases and hepatocellular carcinoma, and we are in late-stage development in both indications. In addition, A28 is preparing to study the benefits of AT-101 in combination with immuno-oncology therapeutics in various solid tumors with liver metastases. Our goal at A28 is to deliver innovative, game-changing cancer care to patients worldwide.